Lowest Price Guaranteed From USD 4,799
Companies Covered
47
Pages
123
View Count
7848
The small scale bioreactors market, which includes mini bioreactor and micro bioreactor, is estimated to be worth $1.2 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 8% during the forecast period. With several blockbuster therapies (such as Humira®, Rituxan®, Lantus®, Avastin®, Herceptin® and Remicade®) and a robust pipeline of product / therapy candidates, the global market of biopharmaceuticals is anticipated to witness significant growth in the next few years. However, it has been established that biologic drug development is a complex, time-consuming and capital-intensive process. These complex molecules require highly engineered specialized equipment, innovative downstream technologies, optimal storage and handling conditions, to ensure safety, efficacy and stability. In addition to the development of biologics, there remains a need to improve productivity, growth medium, process development and process optimization. Over time, a variety of advanced technologies and process analytical tools have been developed to accelerate the overall process. Traditionally, the process involves screening of cell lines in shake flask cultures, testing of successful candidates in bench-top bioreactors prior to pilot-scale studies. The need to carry out a large number of cell cultivations has resulted in the deployment of small-scale bioreactor systems, also known as mini bioreactors, which can process culture volume ranging from 250 mL to 15 L and offer a high-throughput solution to process development. These mini bioreactors allow scaling-down mammalian and microbial cell processes, scaling up the production by generating products in a more concentrated form. In addition, mini bioreactors enable faster experimental throughput at relatively lower costs and allow parallel bioprocessing of samples, thereby reducing the downtime and increasing the number of batches produced in a given period of time.
Presently, more than 55 mini bioreactors, developed by around 30 companies, are available for high-throughput media cultivation, process development and optimization. The stakeholders are taking several initiatives to incorporate a variety of features for monitoring of different control parameters, such as CO2 levels, dissolved oxygen, pH and temperature ranges, thereby allowing the users to analyze and determine essential conditions of the culture environment and optimize the overall performance. Further, the growing interest in precision medicine has also brought up the demand for small-scale production and fast turn-around time of such products. Driven by the growing biopharmaceutical pipeline, the need for efficient and faster process development and manufacturing solutions, the overall small scale bioreactors market is anticipated to witness steady market growth during the forecast period.
![]() |
![]() |
![]() |
Examples of key companies engaged in small scale bioreactors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Eppendorf, Biosan, Bionet, Pall Corporation, Merck Millipore, Sartorius, Cytiva and Distek. It is interesting to note that in July, 2022, PBS Biotech entered into a supply agreemetn with Stemcell Technologies to make its PBS-MINI Bioreactor available to researchers therough Stemcell Technologies. This small scale bioreactors market report includes an easily searchable excel database of all the companies providing mini bioreactor and micro bioreactor, worldwide.
Several recent developments have taken place in the field of mini bioreactors and micro bioreactors. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Small Scale Bioreactors Market, 2022-2035: Distribution by Type of Cell Culture (Mammalian, Microbial, Viral, Insect and Others), Mode of Operation (Batch/Fed-Batch and Continuous), End User (Biopharmaceutical Industry and Academic Institutes) and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts’ market report features an extensive study of the current landscape, market size and the likely future potential of companies manufacturing mini bioreactors and micro bioreactors, during the forecast period. The market research report also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in small scale bioreactors market.
![]() |
![]() |
![]() |
In addition to other elements, the study includes:
One of the key objectives of this market research report is to understand the primary growth drivers and estimate the future market size of small scale bioreactors market. Based on multiple parameters, such as overall biopharmaceutical manufacturing market, overall single-use bioreactors market, share of mini bioreactors and micro bioreactors technologies, and likely adoption trends, we have provided an informed estimate on the market evolution during the forecast period 2022-2035. The market report also features the likely distribution of the current and forecasted opportunity within the small scale bioreactors market across various segments, such as [A] type of cell culture (mammalian, microbial, viral, insect and others), [B] mode of operation (batch/fed-batch reactor and continuous reactor), [C] end-user (biopharmaceutical / pharmaceutical industries and academic / research institutes) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
![]() |
![]() |
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.